

# **EFFICACY OF LOSARTAN IN PRIMARY PROPHYLAXIS OF OESOPHAGEAL VARICEAL BLEEDING DUE TO PORTAL HYPERTENSION**

*Thesis Submitted In Fulfillment For  
The Master Degree In Tropical Medicine*

***AHMED MOHAMED KHAIRY ALY***

MB.B.Ch

## **SUPERVISORS**

***PROF. DR. MOHAMED SERAG EL-DIN ZAKARIA***

Professor of Tropical Medicine  
Faculty of Medicine – Cairo University

***DR. MOHAMED SALAH ABD EL-BARY***

Ass. Professor of Tropical Medicine  
Faculty of Medicine – Cairo University

***DR. KHALED MOHAMED SERAG EL-DIN***

Lecturer of Tropical Medicine  
Faculty of Medicine – Cairo University

Faculty of Medicine

Cairo University

2008

## **Abstract**

This study was designed to evaluate efficacy of Losartan in the primary prevention of oesophageal variceal bleeding and to compare it with that of prophylactic EVL.

It included 40 patients with liver cirrhosis and grade III- IV varices and negative history of variceal bleeding. Both groups were subjected to thorough history taking, clinical examination, laboratory investigations, abdominal ultrasonography, doppler, duplex ultrasonography and upper GI endoscopy. Patients were randomly allocated to receive either EVL or Losartan 50 mg/day and were followed up after three months.

Key Words :

Angiotensin converting enzyme - computerized tomography - Endoscopic Variceal Band Ligation .

## *Acknowledgement*

*First of all, Thanks to GOD, without his will, nothing could have been achieved.*

*My gratitude to **Prof. Dr. Serag Zakaria**, head of Tropical Medicine department, Cairo University for his magnificent encouragement, care and support. Thanks for always being a father and guidance before being a teacher.*

*My deep thanks and appreciation to **Dr. Mohamed Salah**, assistant professor of Tropical Medicine, Cairo University, for his strict supervision and revision of this work, he gave me much of his time, experience and support. His valuable comments, efforts and collaboration were the causes to complete this work properly, so no words can express my gratitude to him.*

*I would like to thank **Dr. Khaled Serag**, Lecturer of Tropical Medicine, Cairo University, for his kindness, and generous help.*

*My deepest gratitude for all members of the endoscopy unit for helping me in completing this work and I would like to thank **Prof. Dr. Sameh Labib** for the facilities he gave me to perform this work.*

*To all my professors, to whom I have the honor to belong, to my professors who welcomed me, encouraged and supported me, who taught and advised me, who gave me their confidence, who trained me and pushed me forwards with special appreciation to **Prof. Dr. Gamal Esmat** for his generous care, advice and help.*

*I wish to express to all my colleagues in Tropical medicine department, Cairo University, my deepest appreciation. Thanks for their help and endless support.*

*I would like to thank Amrya pharmaceutical company for partial support as it provided us with free medical samples of Losartan to perform our study.*

*I would like to thank my family for their endless support and care for my whole life. They were always helping and encouraging me to continue and finish this work, I really owe to them so much.*

*Last, but certainly not least, I owe to the patients included in this study, the whole of it and to all our Kasr El-Aini patients my own life. May God alleviate their sufferings and may all our efforts be just for their own benefit.*

## LIST OF TABLES

<b>Table I</b>	Action of vasoactive agents on HSC.	<b>32</b>
<b>Table II</b>	Pugh's Modification of Child's Classification.	<b>38</b>
<b>Table III</b>	Appearance of portosystemic collaterals by abdominal ultrasonography.	<b>57</b>
<b>Table1</b>	Age of the studied patients.	<b>105</b>
<b>Table2</b>	Sex distribution of the studied patients.	<b>105</b>
<b>Table 3</b>	Clinical findings in the examined groups of patients.	<b>106</b>
<b>Table 4</b>	Laboratory data and MELD score of the studied groups of patients.	<b>106</b>
<b>Table 5</b>	Modified Child's score of the studied groups of patients.	<b>107</b>
<b>Table 6a</b>	Ultrasonographic assessment of liver and spleen for the studied groups of patients.	<b>108</b>
<b>Table 6b</b>	Ultrasonographic assessment of Ascites in the studied groups of patients.	<b>109</b>
<b>Table 6c</b>	Ultrasonographic assessment of hepatic veins flow pattern.	<b>110</b>
<b>Table 6d</b>	Ultrasonographic assessment of Portal vein direction of blood flow.	<b>111</b>

<b>Table 6e</b>	Pretreatment portal vein and splenic vein doppler data of the studied groups.	<b>112</b>
<b>Table 6f</b>	Portosystemic collaterals in the studied groups of patients.	<b>113</b>
<b>Table 7</b>	Endoscopic features seen by upper GI endoscopy in the studied patients.	<b>115</b>
<b>Table 8</b>	MAP in the group1 of patients both pre and 3 months post treatment.	<b>116</b>
<b>Table 9</b>	Laboratory data and MELD score of the group1 of patients both pre and 3 months post treatment.	<b>116</b>
<b>Table 10</b>	Modified Child score of group1 of patients both pre and 3 months post treatment.	<b>117</b>
<b>Table 11</b>	Ultrasonographic assessment of liver and spleen of group1 of patients both pre and 3 months post treatment.	<b>118</b>
<b>Table 12</b>	Ultrasonographic assessment of ascites both pre and 3 months post treatment.	<b>118</b>
<b>Table 13</b>	Ultrasonographic assessment of portosystemic collaterals both pre and 3 months post treatment.	<b>119</b>
<b>Table 14</b>	Ultrasonographic assessment of pattern of hepatic veins both pre and 3 months post treatment.	<b>120</b>

<b>Table 15</b>	Ultrasonographic assessment of portal vein direction of blood flow in group1 of patients both pre and 3 months post treatment.	<b>120</b>
<b>Table 16</b>	Changes in portal vein and splenic vein doppler data in group1 of patients both pre and 3 months post treatment.	<b>121</b>
<b>Table 17</b>	Endoscopic assessment of grade of oesophageal varices both pre and 3 months post treatment.	<b>123</b>
<b>Table 18</b>	Endoscopic assessment of presence of gastro-oesophageal extension both pre and 3 months post treatment.	<b>123</b>
<b>Table 19</b>	Endoscopic assessment of grade of congestive gastropathy both pre and 3 months post treatment.	<b>124</b>
<b>Table 20</b>	Endoscopic presence of signs of impending rupture both pre and 3 months post treatment.	<b>124</b>
<b>Table 21</b>	Comparison between patients with improved grade of varices and those with no improvement in grade of varices in Losartan group as regards to pretreatment data.	<b>125</b>
<b>Table 22</b>	MAP in the group2 of patients both pre and 3 months post variceal obliteration by EVL.	<b>128</b>
<b>Table 23</b>	Laboratory data and MELD score of the group1 of patients both pre and 3 months post variceal obliteration by EVL.	<b>129</b>

<b>Table 24</b>	Modified Child score of group2 of patients both pre and 3 months post variceal obliteration by EVL.	<b>130</b>
<b>Table 25</b>	Ultrasonographic assessment of liver and spleen of group2 of patients both pre and 3 months post variceal obliteration by EVL.	<b>130</b>
<b>Table 26</b>	Ultrasonographic assessment of ascites both pre and 3 months post variceal obliteration by EVL.	<b>131</b>
<b>Table 27</b>	Ultrasonographic assessment of portosystemic collaterals both pre and 3 months post variceal obliteration by EVL.	<b>132</b>
<b>Table 28</b>	Ultrasonographic assessment of pattern of hepatic veins both pre and 3 months post variceal obliteration by EVL.	<b>132</b>
<b>Table 29</b>	Ultrasonographic assessment of portal vein direction of blood flow in group1 of patients both pre and 3 months post variceal obliteration by EVL.	<b>133</b>
<b>Table 30</b>	Changes in portal vein and splenic vein doppler data in group2 of patients both pre and 3 months post variceal obliteration by EVL.	<b>134</b>
<b>Table 31</b>	Endoscopic assessment of grade of congestive gastropathy both pre and 3 months post variceal obliteration by EVL.	<b>135</b>
<b>Table 32</b>	Endoscopic assessment of presence of gastro-oesophageal extension type I both pre and 3 months post variceal obliteration by EVL.	<b>135</b>



<b>Table 33</b>	<b>Endoscopic assessment of grade of congestive gastropathy both pre and 3 months post variceal obliteration by EVL.</b>	<b>136</b>
<b>Table 34</b>	<b>Endoscopic assessment of presence of signs of impending rupture both pre and 3 months post variceal obliteration by EVL.</b>	<b>137</b>
<b>Table 35</b>	<b>Changes between baseline and 3months post treatment with Losartan and Changes between baseline and 3months post obliteration of oesophageal varices by EVL as regard MAP, modified Child score, MELD score, serum creatinine, sonographic and doppler parameters, and Endoscopic features.</b>	<b>137</b>

## LIST OF FIGURES

<b><u>Figure I</u></b>	<b>The anatomy of the portal venous system.</b>	<b>6</b>
<b><u>Figure II</u></b>	<b>Porto-systemic collaterals.</b>	<b>9</b>
<b><u>Figure III</u></b>	<b>The pathophysiology of PHT in cirrhosis.</b>	<b>14</b>
<b><u>Figure IV</u></b>	<b>Phenotypic features of HSC activation during liver injury and resolution.</b>	<b>39</b>
<b><u>Figure V</u></b>	<b>Types of gastric varices.</b>	<b>43</b>
<b><u>Figure VI</u></b>	<b>Practice guidelines for primary prophylaxis of oesophageal varices.</b>	<b>60</b>
<b><u>Figure VII</u></b>	<b>Effects of the angiotensins.</b>	<b>79</b>
<b><u>Figure VIII</u></b>	<b>RAAS.</b>	<b>80</b>

## LIST OF ABBREVIATIONS

- **AASLD:** American Association for the Study of Liver Diseases.
- **ACE:** Angiotensin converting enzyme.
- **AT1:** angiotensin type 1.
- **AT2:** angiotensin type 2.
- **AT II:** angiotensin-II.
- **CI:** congestion Index.
- **CSPH:** clinically significant portal hypertension.
- **CT:** computerized tomography.
- **ECM:** extracellular matrix
- **EUS:** endoscopic ultrasonography.
- **ET:** endothelin.
- **EVL:** Endoscopic Variceal Band Ligation
- **GFR:** glomerular filtration rate.
- **GOVs:** gastro-oesophageal varices.
- **HSC:** hepatic stellate cells.
- **HTN:** hypertension.
- **HVPG:** hepatic venous pressure gradient.
- **IGVs:** isolated gastric varices.
- **IMN:** isosorbide-5-mononitrate.
- **MAP:** mean arterial pressure.
- **MCP-1:** monocyte chemotactic protein 1.
- **MELD:** model of end stage liver disease.
- **MMP-2:** metalloproteinase 2.
- **MRI:** magnetic resonance imaging.
- **NO:** nitric oxide.
- **NOS:** nitric oxide synthetase.

- **PDGF**: platelet-derived growth factor.
- **PG**: prostaglandin.
- **PHT**: portal hypertension.
- **PV**: portal vein.
- **PVF**: portal vein volume flow.
- **RA**: retinoic acid
- **RAAS**: renin angiotensin activating system.
- **SD**: standard deviation.
- **SMV**: superior mesenteric vein.
- **SV**: splenic vein.
- **SVF**: splenic vein volume flow
- **TGF- $\beta$** : transforming growth factor  $\beta$ .
- **TIMP**: Tissue inhibitor of metalloproteinase.
- **TIPS**: transjugular intrahepatic Portosystemic shunt.
- **TNF  $\alpha$** : tumor necrosis factor  $\alpha$ .
- **5-HT**: 5-hydroxytryptamine.

## TABLE OF CONTENTS

Introduction and aim of the work.....	<b>1</b>
Review of literature.....	
<b><u>Chapter I:</u></b> Anatomy and physiology of portal venous system	<b>5</b>
<b><u>Chapter II:</u></b> Pathophysiology of portal hypertension	<b>11</b>
<b><u>Chapter III:</u></b> Stellate cells	<b>27</b>
<b><u>Chapter IV:</u></b> Diagnosis of portal hypertension	<b>35</b>
<b><u>Chapter V:</u></b> Doppler sonography in portal hypertension	<b>50</b>
<b><u>Chapter VI:</u></b> Primary prevention of bleeding from esophageal varices	<b>58</b>
<b><u>Chapter VII:</u></b> Angiotensin converting enzyme receptor antagonist (Losartan)	<b>76</b>
Patients and Methods.....	<b>91</b>
Results.....	<b>104</b>
Discussion.....	<b>139</b>
Summary and Conclusions.....	<b>147</b>
Recommendations.....	<b>150</b>
References.....	<b>151</b>
.....الملخص العربي	

## INTRODUCTION

Portal hypertension (PHT) is a common complication of liver cirrhosis. Cirrhotic patients with PHT develop oesophageal varices and are at very high risk of variceal bleeding (*D'Amico and Luca, 1997*). The incidence of oesophageal varices development is approximately 5% per year in patients with cirrhosis, and the progression from small to large varices occur in 10% to 20% of cases after 1 year. In the 2 years following the first detection of oesophageal varices, the risk of variceal bleeding ranges between 20% to 30% and results in a mortality of 25% to 50% within a week of the first bleeding episode (*D'Amico et al., 2001*). The frequency of bleeding from large varices is 30-53% compared with 5-18% for small varices (*de Franchis, 2000*).

Primary prophylaxis of oesophageal variceal haemorrhage is an important issue in the management of PHT. Prophylaxis is that which is used to prevent disease (*Shahi and Sarin, 1998*).

Different treatments have been proposed to prevent first variceal bleeding. Surgical portocaval shunts and endoscopic sclerotherapy significantly reduce first variceal bleeding but at the price of increased side effects and, in some studies, higher mortality. Therefore, they are considered unsuitable. Since PHT reflects elevated splanchnic blood flow and increased intrahepatic vascular resistance, a goal of drug intervention has been to normalize hepatic hemodynamics and reduce vascular resistance. Certain drugs accomplish this by reducing portal blood flow, some by reducing intrahepatic vascular resistance and others by mechanisms that have not been completely clarified (*Lebrech, 1998*).

Non-selective  $\beta$ -blockers have proved effective in reducing portal pressure by lowering splanchnic blood inflow and are used in primary and secondary prevention of variceal bleeding. However, the mean decrease in portal pressure in response to propranolol is only approximately 15% and one third of cirrhotic

patients do not respond despite adequate blockade (*Vlachogiannakos et al, 2001*).

Despite the fact that  $\beta$ -blockers were the main stay for the primary prevention of variceal bleeding, results of EVL in terms of efficacy and safety are promising (*Bashin and Malhi, 2002*).

During the last decade, increased knowledge of the pathophysiology of PHT has resulted in the use of new pharmacological targets; most importantly for the reduction of intrahepatic resistance, which is now recognized to be due in part to activated stellate cell contraction (myofibroblasts) (*Sims, 1986*). Orally active angiotensin II (AT II) receptor antagonists represent a recent therapeutic development in the inhibition of RAAS (renin-angiotensin-aldosterone system) (*Burnier and Brunner, 2000*). The RAAS is usually activated in patients with liver cirrhosis and this represents a homeostatic response to counterbalance the vasodilatation, arterial hypotension, and renal hypoperfusion observed in portal hypertension. Plasma renin activity is elevated in cirrhotics and is correlated with the hepatic venous pressure gradient (HVPG). AT II is considered a potential mediator of intrahepatic portal hypertension because its plasma levels are elevated in cirrhosis (*Vlachogiannakos et al, 2001*). Infusion of AT-II induces a rise in portal pressure (*Ballet et al, 1988*), Enhancement of the adrenergic vasoconstrictor influence on the portal system (*Goodfriend et al, 1996*), direct contractile influence on activated stellate cells, and sodium and fluid retention induced by stimulation of aldosterone secretion (*Pinzani et al, 1992*) are possible mechanisms that contribute to the portal hypertensive effect of AT II.

Hence, in theory, blockade of the RAAS by angiotensin converting enzyme (ACE) inhibitors/AT-II receptor antagonists should be beneficial for improvement of fluid and salt secretion and reduce portal pressure in cirrhotic patients. ACE inhibitors block the RAAS preventing the conversion of inactive angiotensin I to